ArticlePloS one2014
Cardiovascular risks in relation to daidzein metabolizing phenotypes among Chinese postmenopausal women.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial.Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2016Trial
- Research protocol: effect of natural S-equol on blood pressure and vascular function--a six-month randomized controlled trial among equol non-producers of postmenopausal women with prehypertension or untreated stage 1 hypertension.BMC complementary and alternative medicine · 2016Trial
- Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial.The American journal of clinical nutrition · 2016Trial
- Association of Dietary Animal and Plant Protein Composition with All-Cause Mortality: 24-Year Population-Based Cohort Study.Nutrients · 2026Article
- Cardiovascular disease risk factors in women with O-desmethylangolensin producing and non-producing gut microbial metabotypes: an observational study.BMC cardiovascular disorders · 2026Observational
- Urinary Equol and Equol-Predicting Microbial Species Are Favorably Associated With Cardiometabolic Risk Markers in Chinese Adults.Journal of the American Heart Association · 2024Article
- Association between equol producers and type 2 diabetes mellitus among Japanese older adults.Journal of diabetes investigation · 2023Article
- Flavonoid intake is associated with lower all-cause and disease-specific mortality: The National Health and Nutrition Examination Survey 2007-2010 and 2017-2018.Frontiers in nutrition · 2023Article
- Association between lignan polyphenol bioavailability and enterotypes of isoflavone metabolism: A cross-sectional analysis.PloS one · 2023Article
- Health Effects of Soy Isoflavones and Green Tea Catechins on Cancer and Cardiovascular Diseases Based on Urinary Biomarker Levels.Molecules (Basel, Switzerland) · 2022Review
- Association between Equol Production Status and Nonalcoholic Steatohepatitis.International journal of molecular sciences · 2021Article
- Insight into Polyphenol and Gut Microbiota Crosstalk: Are Their Metabolites the Key to Understand Protective Effects against Metabolic Disorders?Antioxidants (Basel, Switzerland) · 2020Review
- Role of S-Equol, Indoxyl Sulfate, and Trimethylamine N-Oxide on Vascular Function.American journal of hypertension · 2020Review
- Phytoestrogens and Their Health Effect.Open access Macedonian journal of medical sciences · 2019Review
- Effect of S-equol and Soy Isoflavones on Heart and Brain.Current cardiology reviews · 2019Review
- Personalised Interventions-A Precision Approach for the Next Generation of Dietary Intervention Studies.Nutrients · 2017Review
- Addressing the inter-individual variation in response to consumption of plant food bioactives: Towards a better understanding of their role in healthy aging and cardiometabolic risk reduction.Molecular nutrition & food research · 2017Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies suggested that the inter-individual differences in metabolizing isoflavone daidzein to equol or O-desmethylangolensin (ODMA) might explain the inconsistency of the soy/isoflavones efficacy on cardiovascular health.
objectivesThe study aims to evaluate the relationship between equol and ODMA phenotypes and cardiovascular risks with habitual isoflavone consumption in Chinese postmenopausal women.
methodsThis is a cross-sectional study among 726 prehypertensive postmenopal women who were screened for a randomized controlled trial. 648 women returned a daidzein-challenged urine samples for determination of equol and O-DMA production. 595 attended clinic visits for assessment of cardiovascular risks including body composition, blood pressure (BP), serum lipids, uric acid, high sensitivity C-reactive protein (hs-CRP), fasting glucose and free fatty acid (FFA).
resultsThe prevalences of equol and O-DMA producers were 53.2% and 60.9% respectively. Equol producers had higher fat free mass (p = 0.001), lower systolic (p = 0.01) and diastolic (p = 0.01) BP, serum triglyceride (p = 0.023), hs-CRP (p = 0.015) and FFA (p = 0.001) than non-producers. O-DMA producers had lower body fat% (p = 0.032), SBP (p = 0.02), total cholesterol (p = 0.002) than non-producers. The significant differences remained after further adjustment for potential confounders. The habitual soy isoflavones intake had little relation to cardiovascular risk factors in either equol/O-DMA producer phenotypes.
conclusionEquol/O-DMA producers had more favorable cardiovascular risk profiles than non-producers in prehypertensive postmenopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.